secwatch.observer — SEC 8-K summary
======================================

Issuer:     GILEAD SCIENCES, INC. (GILD)
CIK:        0000882095
Form:       8-K
Filed at:   2022-02-01T23:59:59+00:00
Accession:  0000882095-22-000003
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gilead Q4 GAAP EPS $0.30, revenue $7.2B (-2% YoY); 2022 guidance $23.8-24.3B
----------------------------------------------------------------------------

- GAAP diluted EPS $0.30 vs $1.23 YoY; non-GAAP $0.69 vs $2.19 (includes $1.25B legal charge)
- Q4 product sales $7.2B (-2% YoY); ex-Veklury up 8% to $5.8B
- Biktarvy sales up 22% YoY to $4.5B; Cell Therapy up 47% to $239M
- 2022 guidance: product sales $23.8-24.3B; GAAP EPS $4.70-5.20; non-GAAP EPS $6.20-6.70
- Cash flow: $3.2B operating; debt repayment $1B; dividends $894M; cash $7.8B at Dec 31

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882095/000088209522000003/0000882095-22-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882095/000088209522000003/gild-20220201.htm
  HTML page:      https://secwatch.observer/filing/0000882095-22-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer